In January 2024, the FDA updated its guidance on CAR-T therapies, emphasizing the need for enhanced safety and quality measures. This update followed a series of warnings regarding the risk of T cell ...

Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.

T cells play a big role in bringing cell and gene therapies to patients. Despite this clinical potential, scientists developing T cell therapies such as chimeric antigen receptor (CAR)-T cells, ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

Two molecular control factors play a decisive role in what is known as splicing, the cutting and assembly of mature messenger RNA—a prerequisite for protein synthesis in the cell. The poorly ...

Successfully producing large quantities of biotherapeutics, including monoclonal antibodies and recombinant protein products, depends on robust and reliable cell line development (CLD). Issues that ...